flutamide has been researched along with Lymph Node Metastasis in 19 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | 1.30 | Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. ( Lubos, W; Schmeller, N, 1997) |
| "Patients with node-positive prostate cancer that is regionally localized (T1-4, N1-3, M0) have a relatively poor prognosis when a single-treatment modality such as radical surgery, definitive radiotherapy, or androgen ablation is used." | 1.29 | Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. ( Pollack, A; Sands, ME; Zagars, GK, 1995) |
| "A 75-year-old patient presented with a superior vena cava syndrome (SVCS) lasting 3 years." | 1.29 | Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome. ( Bellas, C; Hernanz, I; Molina, JP; Montalbán, C; Moreno, MA, 1993) |
| "We describe a florid xanthomatous histiocytic reaction in the pelvic lymph nodes of a patient treated with androgen deprivation therapy prior to radical prostatectomy." | 1.29 | Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. ( Gormley, EA; Schned, AR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 12 (63.16) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steinkamp, MP | 1 |
| O'Mahony, OA | 1 |
| Brogley, M | 1 |
| Rehman, H | 1 |
| Lapensee, EW | 1 |
| Dhanasekaran, S | 1 |
| Hofer, MD | 1 |
| Kuefer, R | 1 |
| Chinnaiyan, A | 1 |
| Rubin, MA | 1 |
| Pienta, KJ | 1 |
| Robins, DM | 1 |
| Metzner, C | 1 |
| Nöldge, G | 1 |
| Delling, G | 1 |
| Oehler, U | 1 |
| Nawroth, P | 1 |
| Kasperk, C | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Roach, M | 1 |
| Bae, K | 1 |
| Speight, J | 1 |
| Wolkov, HB | 1 |
| Rubin, P | 1 |
| Lee, RJ | 1 |
| Lawton, C | 1 |
| Valicenti, R | 1 |
| Grignon, D | 1 |
| Pilepich, MV | 1 |
| Sands, ME | 1 |
| Pollack, A | 1 |
| Zagars, GK | 1 |
| Cheson, BD | 1 |
| Kaplan, RS | 1 |
| Phillips, PH | 1 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Reuter, V | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Fair, WR | 1 |
| Garin-Chesa, P | 1 |
| Cher, ML | 1 |
| Shinohara, K | 1 |
| Breslin, S | 1 |
| Vapnek, J | 1 |
| Carroll, PR | 1 |
| Whittington, R | 1 |
| Malkowicz, B | 1 |
| Barnes, MM | 1 |
| Broderick, GA | 1 |
| Van Arsdalen, K | 1 |
| Dougherty, MJ | 1 |
| Wein, AJ | 1 |
| Jindal, PK | 1 |
| Hota, D | 1 |
| Prasad, KV | 1 |
| Nijhawan, R | 1 |
| Vaidyanathan, S | 1 |
| Newling, DW | 1 |
| Denis, L | 1 |
| Vermeylen, K | 1 |
| Montalbán, C | 1 |
| Moreno, MA | 1 |
| Molina, JP | 1 |
| Hernanz, I | 1 |
| Bellas, C | 1 |
| Schned, AR | 1 |
| Gormley, EA | 1 |
| Schmeller, N | 1 |
| Lubos, W | 1 |
| Gómez Veiga, F | 1 |
| Lorenzo Patiño, MJ | 1 |
| Díaz Bermúdez, J | 1 |
| Duarte Novo, J | 1 |
| Alvarez Castelo, L | 1 |
| Chantada Abal, V | 1 |
| Sánchez Rodríguez, J | 1 |
| González Martín, M | 1 |
| Renshaw, AA | 1 |
| Granter, SR | 1 |
| Cecchi, M | 1 |
| Sepich, CA | 1 |
| Bertolini, L | 1 |
| Catastini, M | 1 |
| Di Benedetto, A | 1 |
| Ippolito, C | 1 |
| Pazzagli, I | 1 |
| Summonti, D | 1 |
| Bonadio, AG | 1 |
| Fiorentini, L | 1 |
| Prout, GR | 1 |
| Kliman, B | 1 |
| Daly, JJ | 1 |
| Maclaughlin, RA | 1 |
| Griffin, PP | 1 |
| Zaragoza, MR | 1 |
| Grossman, HB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)[NCT02303327] | Phase 3 | 296 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.[NCT01800058] | 68 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy[NCT03296124] | 0 participants (Actual) | Observational | 2017-12-07 | Withdrawn (stopped due to This project currently does not have any subjects enrolled due to other PI priorities.) | |||
| A Phase II Study of Dose-Escalated Proton-Based Radiation Therapy Delivered With a Simultaneous Integrated Boost (SIB) to Intraprostatic Tumors (IPT) Visible on Pretreatment Magnetic Resonance Image[NCT03624660] | 100 participants (Anticipated) | Interventional | 2018-09-24 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as freedom from distant metastasis (NCT01800058)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 64 | 1 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: 9 - 12 months post-radiotherapy in cases with positivation after basal visit
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 12 | 1 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: Post-neoadjuvant hormone therapy and prior to radiotherapy
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | No Data | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 54 | 8 | 3 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: Post-radiotherapy
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | No Data | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 48 | 11 | 6 |
Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline. (NCT01800058)
Timeframe: Basal
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 60 | 5 |
3 trials available for flutamide and Lymph Node Metastasis
| Article | Year |
|---|---|
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies | 1995 |
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver | 1993 |
16 other studies available for flutamide and Lymph Node Metastasis
| Article | Year |
|---|---|
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Topics: Amino Acid Substitution; Anilides; Antineoplastic Agents; Autopsy; Cycloheximide; DNA Primers; Fluta | 2009 |
[Bone metastasis of prostatic cancer imitating Paget's sarcoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neopla | 2006 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
Topics: Adenocarcinoma; Adult; Aged; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1995 |
Clinical trials referral resource. Prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Comb | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Flutamid | 1995 |
Advanced prostatic carcinoma in a 19-year-old male.
Topics: Adult; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Interferon alpha-2; Interferon-alpha | 1994 |
Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome.
Topics: Adenocarcinoma; Aged; Biopsy; Flutamide; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Prostatic | 1993 |
Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progressio | 1997 |
[Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; | 1997 |
Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemother | 2000 |
[Adenoid cystic carcinoma of the prostate. Clinical case].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Carcinoma, Adenoid Cysti | 2000 |
In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
Topics: Aged; Culture Techniques; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Humans; Lymphatic Meta | 1976 |
Objective treatment response to endocrine therapy in metastatic prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Combined Modality Therapy; Estrogens; Flutamide; Humans; Lymphatic M | 1992 |